Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesPharmacy & Specialty DrugsBlue KC PDL Coverage & Prior Auth Update | OpenPay…
    Ask Trek AI about this page

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    CurrentBlue KCPolicy WF14556489-D 082224

    Prescription Drug List (PDL) — Drug Utilization Management and Formulary Coverage

    Customize your policy alerts

    Sign up for Blue KC Policy WF14556489-D 082224 alerts

    Get alerted when Policy WF14556489-D 082224 changes without checking for updates manually.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    Governs prescription drug coverage, tiers, prior authorization, quantity limits, step therapy, specialty pharmacy use, and related utilization management for Blue KC HMO, PPO, and EPO members with prescription drug benefits.

    Policy Summary
    PayerBlue KC
    PolicyPrescription Drug List (PDL) — Drug Utilization Management and Formulary Coverage
    Policy CodePolicy WF14556489-D 082224
    Key ActionPrescribers must submit an electronic prior authorization request via the BlueKC provider portal when a drug is marked PA or when requesting exceptions to coverage rules.
    Change TypeAdministrative — no material clinical changes
    Effective DateJan 1, 2025
    Next Review Date
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    QuarterlyPDL review frequency
    34-daySpecialty supply limit
    44,000+Member pharmacy network
    $0 costPreferred syringe supply
    PA / QL / STUtilization flags observed

    Coverage and Formulary Rules

    General PDL coverage criteria

    Coverage and utilization management apply as follows for drugs on the PDL:

    PDL governance and evaluation: Medications on the PDL are selected by the Blue KC Medical and Pharmacy Management Committee based on safety, effectiveness, adverse events, proven advantages, and cost.

    Quarterly review by committee

    Utilization management types: Drugs may be subject to prior authorization, quantity limits, step therapy, or specialty pharmacy requirements as specified in the PDL.

    Prescribers may request exceptions via electronic prior authorization

    Specialty drugs: Specialty medications require dispensing through a network Specialty Pharmacy and are limited to a 34-day supply; specialty pharmacies provide care coordination and clinical support.34-day supply
    Policy Summary
    PayerBlue KC
    PolicyPrescription Drug List (PDL) — Drug Utilization Management and Formulary Coverage
    Policy CodePolicy WF14556489-D 082224
    Key ActionPrescribers must submit an electronic prior authorization request via the BlueKC provider portal when a drug is marked PA or when requesting exceptions to coverage rules.
    Change TypeAdministrative — no material clinical changes
    Effective DateJan 1, 2025
    Next Review Date
    SourceLink
    On This Page
    Coverage and Formulary RulesDrug Index and Coding ExamplesPrior Authorization, Step Therapy, and DocumentationInitial Therapy / Step Therapy RulesQuantity Limits by Drug / Example LimitsSpecialty Pharmacy and Site-of-Care RequirementsPolicy Background and GovernanceTerms and Abbreviations

    Most specialty medications must be filled at a network Specialty Pharmacy (Optum Specialty Pharmacy)

    Formulary coverage with utilization management

    Covered when plan rules and utilization management requirements are met:

    General conditions: Member has a valid prescription for the drug or syringe/needle; for syringe/needles, member must be taking medications requiring injection; nonpreferred syringe/needle products are covered at a nonpreferred copay while Techlite/Arkray supplies are covered at $0 cost.

    See formulary entries for copay and tier information

    Prior authorization and quantity limits: If a drug is listed with PA or QL, coverage requires prior authorization or adherence to quantity limits as specified on the formulary entry.

    Examples in analgesics include buprenorphine and certain fentanyl patches which are listed with PA and/or QL

    Step therapy: If a drug entry indicates ST, the member must have trial and failure or intolerance of required step agents before the requested drug will be covered.

    ST is defined in abbreviations and applied to several agents in the formulary

    Certain drug classes are not covered under a standard pharmacy benefit unless the member’s plan includes an additional benefit rider. Examples called out by the formulary include fertility, birth control, impotency, and weight-loss therapies; coverage for these classes requires the applicable rider to be on the member’s health plan.

    Syringes and needles are covered only when a prescription is presented and only for members who are taking medications that require injection. The formulary identifies Techlite/Arkray supplies as the preferred syringe/needle supply covered at $0 cost; other syringe and needle products are subject to a nonpreferred brand copay.

    Drug Index and Coding Examples

    Formulary Drug Examplesmixed
    naloxone_hcl_injectionnaloxone hcl injection — Drug Tier = . Restrictions Limits = .
    naloxone_hcl_nasalnaloxone hcl nasal — Drug Tier = G. Restrictions Limits = .
    Drug Name Index (fragment)mixed
    naloxone hcl injectionIndex entry: naloxone hcl injection — see Formulary
    naloxone hcl nasalIndex entry: naloxone hcl nasal — see Formulary
    Drug Name Index (continued)mixed
    NALOXONE_HCL_INJECTIONNo billing codes — product listed in formulary
    NALOXONE_HCL_NASALNo billing codes — product listed in formulary
    Quantity Limits (examples)
    naloxone hcl injectionRestrictions Limits = .
    naloxone hcl nasalDrug Tier = G; Restrictions Limits = .
    Quantity Limits examples
    Example QL - naloxone hcl injectionNo quantity limit specified in source
    Example QL - naloxone hcl nasalNo quantity limit specified in source
    Quantity limit examples
    QL example fragment AConsolidated entry for naloxone products
    QL example fragment BPreserve original restriction notes: none specified
    Quantity limits shown
    Additional QL examplenaloxone entries included with no QL

    Prior Authorization, Step Therapy, and Documentation

    Prior Authorization

    Prior authorization required — general PA requirement callout

    Prior Authorization (PA) is required for many listed drugs in this formulary. Prescribers must obtain approval from Blue KC before the prescription can be filled for items marked PA. Claims for PA-designated products may be denied if authorization is not obtained prior to dispensing.

    • PA applies to multiple drug classes and individual agents as shown in the formulary listings (PA flag).
    • Prescribers may request exceptions or submit electronic PA requests via the Blue KC provider portal: www.BlueKC.com > Providers > Forms > Prior Authorizations for Medications.
    Prior Authorization

    Prior authorization required for selected drugs — PA examples

    Prior authorization is specifically required for many selected drugs identified throughout the formulary (examples include certain analgesics, neurologic agents, metabolic/diabetes products, specialty agents, and biologics). When a drug in the formulary row is annotated with PA, approval is required before coverage.

    • Analgesics: entries such as buprenorphine and tramadol ER are shown with PA flags in the listing.
    • Neurologic / MS agents: fingolimod, glatiramer products, teriflunomide and others are marked PA in the formulary.
    • Metabolic/Diabetes: select GLP‑1 agonists and other branded diabetes products (e.g., MOUNJARO, OZEMPIC, RYBELSUS) carry PA flags.
    • Specialty/high‑cost agents and biologics (e.g., certain enzyme‑replacement or genetic disorder drugs) are marked PA and require prior approval.
    Prior Authorization

    Prior authorization required for listed MS and other agents

    Multiple multiple sclerosis (MS) and other neurologic agents are annotated with PA and quantity limits in the formulary. Prior authorization must be obtained and supporting documentation of medical necessity may be required when requesting these agents.

    • MS agents shown with PA include fingolimod, glatiramer acetate products, glatopa, and teriflunomide (all listed with PA; QL where indicated).
    • Entries include both PA and QL flags — requests should include diagnosis, prior therapies tried, and dosing justification.
    Prior Authorization

    Prior authorization required for select products — PA/QL/ST flags

    Prior authorization is required for select products across several therapeutic areas; these entries are flagged in the formulary and often paired with quantity limits (QL) and/or maintenance (M) or step therapy (ST) requirements. Obtain PA before dispensing to avoid claim denials.

    • Antifungals and antivirals: posaconazole, voriconazole and others have PA flags.
    • Antimigraine and pulmonary hypertension agents: some agents require PA and have QL limits.
    • Insulins, GLP‑1 agents, and other diabetes supplies appear with PA and/or M/QL designations — check each formulary line for PA.
    • Specialty products (G‑S) are frequently PA‑flagged.
    Note

    Prior authorization — none listed in this index fragment

    Some index fragments or portions of the formulary do not list prior authorization rules explicitly. In those segments the formulary is acting as an index or table of contents; absence of a PA flag in that fragment does not guarantee the product is PA‑free — always check the detailed listing for the drug.

    • Index entries list page/location but may not include restriction flags; review the product detail row where PA/QL/ST are shown.
    • When the formulary fragment shows no PA flag, confirm coverage via the provider portal or prior authorization tool.
    Note

    Prior authorization references not included — index sections

    Some index sections do not include prior authorization references or restriction flags. These are index‑only pages and must be cross‑referenced with the full formulary entries to determine PA status.

    • Index pages (drug name → page references) do not display PA/QL/ST codes — see the corresponding formulary section for restriction details.
    Documentation Required

    Syringe/Needle prescription requirement

    Syringes and needles are covered only by prescription and only when used for medications requiring injection. Certain branded supplies (Techlite/Arkray) are covered at $0; other syringe/needle products may be covered only as non‑preferred brand and have specific restrictions.

    • Syringes and needles require a prescription to be covered.
    • Some pen needles and insulin syringe SKUs are marked ST, M, or OTC in the listing — confirm eligibility and any step‑therapy or maintenance limits before dispensing.
    Denial Risk

    Restriction flags that may trigger denial

    Restriction flags in the formulary (PA, QL, ST, M, ACA, OTC) indicate utilization controls that may trigger claim denials or require additional documentation. Entries marked with these flags must follow the corresponding prior authorization, quantity limit, or step therapy process.

    • PA = Prior Authorization: provider must obtain approval prior to dispensing or the drug may not be covered.
    • QL = Quantity Limit: the plan limits the amount covered; exceeding the limit may cause claim denial.
    • ST = Step Therapy: trials of preferred agents may be required before coverage of the requested drug.
    • M = Maintenance; ACA = Affordable Care Act preventive; OTC = Over the counter — these flags affect coverage and may interact with PA/QL/ST rules.
    Step Therapy

    Step therapy/medical necessity denial risk

    When entries include Step Therapy (ST) or Maintenance (M) flags, failure to meet step requirements or to document medical necessity may result in denial. Providers should document prior therapies tried and reasons for failure when requesting an exception or PA.

    • Step therapy examples: gabapentin once‑daily formulations, pregabalin ER, and select neuropathic/neurology agents are annotated ST and QL in the listing.
    • For diabetes and other chronic‑therapy products, ST and M flags appear on various branded agents — supporting documentation of prior trials is required for PA review.
    Note

    No explicit authorization or denial rule — index only fragments

    Some sections of the document are index‑only and do not contain explicit authorization or denial rules. Those sections are intended for navigation; providers must consult the full formulary entry for coverage rules and restriction details.

    • Index entries list locations and do not replace the formulary rows that contain PA/QL/ST flags and documentation guidance.
    • If an index fragment shows no PA or denial language, cross‑reference the detailed listing before taking action.
    Documentation Required

    Quantity limit documentation

    Quantity limits (QL) noted in the formulary imply documentation expectations. When a product is subject to a QL, prescribers should include intended dose, duration, and clinical rationale in PA or exception requests to support coverage above the standard limit.

    • Examples: analgesics and antiemetics include QL specifications (EA/day, ML/day, EA per 365 days).
    • Requests to exceed QL require documentation of medical necessity and prior treatment history.
    Prior Authorization

    Prior authorization / quantity limit handling

    When a formulary entry includes PA and/or QL flags, follow Blue KC’s prior authorization and quantity‑limit handling procedures: obtain PA before dispensing when required, include required supporting clinical documentation, and confirm the approved quantity or refill frequency to avoid denials.

    • Submit electronic PA via the Blue KC provider portal and include diagnosis, prior therapies, and rationale for the requested agent/quantity.
    • Adhere to QL limits and ST requirements; if an exception is requested, provide documentation of trial and failure or clinical contraindication to preferred therapies.

    Initial Therapy / Step Therapy Rules

    Initial therapy (step therapy) rules

    Plan-level initial therapy rules

    Step therapy requirement: When ST is specified on a formulary entry, the member must try specified preferred agent(s) first per plan rules.

    If first-line agents are inappropriate, prescriber must submit prior authorization documenting why alternatives are unsuitable

    Trial and failure: Coverage of the nonpreferred or later-line agent requires documentation of trial and inadequate response or intolerance to the required step agents.

    Documentation submitted via electronic prior authorization form

    Application examples: Step therapy edits are applied to selected drug groups and formulations (examples include certain anticonvulsants, antimigraine agents, specific gabapentin once-daily and pregabalin ER products, and selected insulin/antidiabetic products).

    See formulary entries marked 'ST' for drug-specific step requirements

    Coverage requirementPolicy summary
    Step therapy required when specified on the PDL
    When an entry is marked 'ST' on the PDL, the member must trial the specified preferred agent(s) first; if the prescriber documents that first-line agents are inappropriate, a prior authorization must be submitted documenting why alternatives are unsuitable
    RequirementDetails / prescriber action
    Trial of preferred agent(s) prior to nonpreferred therapy (ST)
    ST requires trial and inadequate response or intolerance to plan-defined preferred agent(s) before coverage of nonpreferred therapy; prescribers may submit an electronic prior authorization to document exceptions
    Agent group / exampleST notation in formulary
    Anticonvulsants (example: oxcarbazepine er)
    Some anticonvulsants are designated 'ST' in the PDL indicating step therapy applies (oxcarbazepine er listed with Restrictions = ST)
    Antimigraine agents (examples: diclofenac potassium for migraine)
    Select antimigraine entries include 'ST' or other restriction flags to indicate step edits apply; formulary entries specify ST where required
    Product examplesFormulary flags
    Gabapentin once-daily formulations (300 mg, 600 mg)
    Entries for gabapentin once-daily are marked 'ST; QL' (e.g., 300 mg Restrictions = ST; QL (6 EA per 1 day); 600 mg Restrictions = ST; QL (3 EA per 1 day))
    Pregabalin ER formulations (82.5 mg, 165 mg, 330 mg)
    Pregabalin ER entries are marked 'ST; QL' indicating step therapy applies with quantity limits per strength (e.g., ST; QL (3 EA per 1 day) or ST; QL (2 EA per 1 day))
    Product categoryST examples / flags
    Dermatologic topical agents (example: imiquimod, pimecrolimus)
    Some dermatologic products are marked 'ST' (e.g., imiquimod external cream 3.75% Restrictions = ST; pimecrolimus Restrictions = ST; QL (2 GM per 1 day))
    Insulin devices and related supplies
    Certain insulin pen needles and related supplies are listed with 'ST' (e.g., insulin pen needles Restrictions = ST; M; OTC) indicating step therapy edits apply to supply items and select insulin-related products
    ProductFormulary flags / limits
    Prucalopride succinate
    Listed with 'ST; QL (1 EA per day)' indicating step therapy applies and a quantity limit of 1 each per day
    ProductFormulary flags
    FEMLYV
    Marked 'ST; M; ACA' on the PDL indicating step therapy applies along with M and ACA restriction markers
    Supply / topical categoryFormulary notation
    Pen needles and related supply items (example: RAYA SURE PEN NEEDLE, VERIFINE pen needles)
    Several pen needle products are listed with 'ST; M; OTC' indicating step therapy edits apply to supply items and some ophthalmic topicals are similarly marked 'ST'
    Ophthalmic topical agents (examples: bromfenac, loteprednol gel)
    Certain ophthalmic topicals carry ST and QL flags (e.g., bromfenac once-daily entries noted ST; QL for specific ML per 365 days) — formulary entries indicate ST where applicable
    Marker on formularyImplication / management
    M (Medical management)
    Entries marked 'M' indicate additional management or medical necessity review may apply; these products may require documentation or limits even when not explicitly ST
    PA (Prior Authorization)
    Products marked 'PA' require prior authorization before coverage; when combined with other flags (e.g., QL or ST) the corresponding procedures (PA submission, adherence to QL, step therapy trial) apply and claims may be denied without meeting requirements

    Quantity Limits by Drug / Example Limits

    inv-80: specialty medications
    Specialty supply limitSpecialty medications are limited to a 34 day supply (specialty pharmacy dispensing).
    Specialty pharmacy requirementMost specialty medications must be filled at a network Specialty Pharmacy (Optum Specialty Pharmacy) to be covered.
    Specialty pharmacy servicesSpecialty pharmacies provide patient care coordinators, clinical staff, overnight shipping, and billing coordination at no additional cost.
    inv-81: Multiple listed agents (examples)
    Assorted QL examplesQL (136 ML per 1 day); QL (13 EA per 1 day); QL (2 EA per 1 day); QL (180 supply per 365 days)
    Buprenorphinebuprenorphine — PA; QL (0.15 EA per day)
    Varenicline (smoking cessation)varenicline tartrate — ACA; QL (180 supply per 365 days)
    Hydromorphone ERhydromorphone HCL ER — PA; QL (2 EA per 1 day)
    inv-82: linezolid oral tablet
    Linezolid oral tablet QLQL (28 EA per 30 days)
    Linezolid formulation notedlinezolid oral suspension reconstituted is listed as Generic (G)
    Class listing sourceLinezolid appears under antibacterials with specified QL in the formulary table of contents.
    inv-83: dabigatran / rivaroxaban
    Dabigatran / Rivaroxaban QLQL (2 EA per 1 day) for dabigatran; rivaroxaban — QL (2 EA per day)
    Formulary placementBoth agents are listed under Anticoagulants with M or QL flags where applicable.
    Provider implicationQuantity limits require dispensing to conform to '2 EA per day' unless PA/exception granted.
    inv-84: ondansetron solution / tablet
    Ondansetron solution QLondansetron HCl oral solution — QL (4 ML per 1 day)
    Ondansetron 24 mg tablet QLondansetron HCl oral tablet 24 mg — QL (0.07 EA per day)
    Formulary locationOndansetron entries appear in the Antiemetics section with QL specifications in the table of contents.
    inv-85: tavaborole
    Tavaborole supply limitQL (84 day supply per 180 days)
    Therapeutic classTavaborole listed under antifungals/dermatologic agents with QL noted.
    Coverage implicationDispensing limited to an 84‑day quantity within any 180‑day period unless exception approved.
    inv-86: eletriptan hydrobromide
    Eletriptan QLQL (12 EA per 30 days)
    Therapeutic areaEletriptan listed under Antimigraine Agents with the 12 per 30 days limit.
    Patient counselingQuantity limit aligns with typical acute migraine dosing frequency limitations.
    inv-87: clorazepate dipotassium 7.5 mg
    Clorazepate 7.5 mg QLQL (12 EA per 1 day)
    Class contextListed among benzodiazepines/sedatives with a 12 per day limit for the 7.5 mg tablet.
    Dispensing notePrescribers should ensure QL adherence; excess quantities may require PA.
    inv-88: lorazepam intensol / concentrate
    Lorazepam intensol / concentrate QLQL (5 ML per 1 day) for lorazepam intensol and lorazepam oral concentrate 2 mg/mL
    Formulation detailBoth intensol and oral concentrate specified with same ML/day limit in formulary.
    Prescriber actionAdhere to ML‑based QL when prescribing concentrate formulations to avoid denial.
    inv-89: dextroamphetamine sulfate oral solution
    Dextroamphetamine solution QLQL (60 ML per 1 day)
    Table locationListed with stimulant formulations; QL indicated in table of contents.
    Clinical implicationHigh volume limits for solution formulations require careful prescribing and monitoring.
    inv-90: dimethyl fumarate starter pack
    Dimethyl fumarate starter pack QLQL (120 EA per 365 days)
    Therapeutic classDimethyl fumarate listed among multiple sclerosis agents with PA; QL noted.
    Coverage noteStarter pack quantity limited to 120 per year unless PA/exception granted.
    inv-91: calcipotriene-betameth diprop ointment
    Calcipotriene‑betameth ointment QLQL (13.4 GM per 1 day)
    Calcipotriene‑betameth suspension QLQL (4 GM per 1 day)
    Topical dosing implicationDifferent formulations have distinct gram‑based QLs; prescribe appropriate formulation/quantity.
    inv-92: calcipotriene-betameth suspension
    Calcipotriene‑betameth suspension QLQL (4 GM per 1 day)
    Formulation distinctionSuspension has a lower gram‑based QL than ointment—check formulation when dispensing.
    Coverage implicationDispensing must match listed formulation QL to avoid claim issues.
    inv-93: pimecrolimus
    Pimecrolimus QLQL (2 GM per 1 day)
    Restriction flagsPimecrolimus also displays ST (step therapy) in the formulary listing.
    Prescriber guidanceStep therapy and QL both apply — submit PA when step/QL exceptions needed.
    inv-94: MOUNJARO
    MOUNJARO QLQL (0.08 ML per 1 day)
    OZEMPIC QLQL (0.11 ML per 1 day)
    RYBELSUS (3 mg) QLQL (60 EA per 365 days)
    inv-95: OZEMPIC
    OZEMPIC QLQL (0.11 ML per 1 day)
    PA/M flagsOZEMPIC is listed with PA; M; QL in the formulary.
    Dispensing noteAdhere to ML/day QL for pen/syringe products unless PA granted.
    inv-96: RYBELSUS ORAL TABLET 3 MG
    RYBELSUS 3 mg QLQL (60 EA per 365 days)
    Restriction flagsRYBELSUS 3 mg also listed with PA; M in other tablet strengths.
    Coverage implication60 tablets per year limit for the 3 mg strength unless PA supports additional supply.
    inv-97: CONTOUR NEXT GEN TEST STRIPS
    CONTOUR NEXT GEN test strips QLQL (10 EA per 1 day) — OTC flag also present
    Product classificationCONTOUR NEXT GEN TEST STRIPS listed under Diabetes Glucose Monitoring with OTC; QL noted.
    Dispensing noteQL limits apply even for OTC‑flagged test strips in formulary listings.
    inv-98: dexlansoprazole
    Dexlansoprazole QLQL (1 EA per day)
    Esomeprazole QLesomeprazole magnesium oral capsule/packet — QL (1 EA per day)
    Formulary contextListed under GERD/acid suppression with M; QL noted for maintenance coverage.
    inv-99: esomeprazole magnesium oral capsule/packet
    Esomeprazole capsule/packet QLQL (1 EA per day)
    Formulary flagShown with M; QL in the formulary table of contents.
    Dispensing implicationAdhere to 1 per day QL for capsules/packets unless exception authorized.
    inv-100: lubiprostone
    Lubiprostone QLQL (2 EA per 1 day)
    Therapeutic classListed under Gastrointestinal Agents with QL noted in table of contents.
    Prescriber actionPrescribe within 2 EA/day limit or submit PA for additional quantity.
    inv-101: mifepristone 300 mg
    Mifepristone 300 mg QLQL (4 EA per 1 day)
    Formulary placementListed with specific EA limit in the hormonal/obstetric section.
    Coverage noteAdhere to 4 tablet limit; additional dispensing would require plan review.
    inv-102: jolessa
    Jolessa QLQL (1 EA per 1 day) — often flagged M; ACA
    Contraceptive flagsMany contraceptives flagged M; ACA indicating preventive coverage status.
    Dispensing implicationOne unit per day QL aligns with typical contraceptive supply rules.
    inv-103: medroxyprogesterone acetate IM suspension
    Medroxyprogesterone IM suspension QLQL (0.02 ML per 1 day)
    Formulary flagListed with ACA; QL in contraceptive/hormonal section.
    Administration noteIM suspension volume limited per QL — check formulation when ordering.
    inv-104: calcitonin (salmon) nasal
    Calcitonin (salmon) nasal QLQL (0.13 ML per 1 day)
    Therapeutic classListed under Metabolic Bone Disease / Osteoporosis with M; QL noted.
    Coverage implicationDaily ML limit applies; dispensing beyond limit requires exception.
    inv-105: ibandronate sodium oral
    Ibandronate oral QLQL (0.04 EA per 1 day)
    Class contextListed under osteoporosis agents with M; QL specified.
    Prescribing noteSmall EA/day QL — ensure appropriate dosing schedule when dispensing.
    inv-106: risedronate sodium 150 mg
    Risedronate 150 mg QLQL (0.15 EA per 1 day)
    Formulary placementRisedronate 150 mg listed under osteoporosis with M; QL noted.
    Dispensing implicationAdhere to EA/day QL unless PA supports alternative supply.
    inv-107: bromfenac ophthalmic solution 0.075%
    Bromfenac ophthalmic QLQL (20 ML per 365 days)
    Once‑daily vs once‑year limitsSpecific bromfenac formulations show QLs stated per 365 days (6.8 ML, 12 ML, 20 ML depending on concentration).
    Ophthalmic implicationYearly ML limits apply for chronic topical ophthalmic therapy.
    inv-108: loteprednol gel
    Loteprednol gel QLQL (20 GM per 365 days)
    Formulation noteLoteprednol gel listed with G‑S class entries and a gram/year limit.
    Prescribing guidanceAdhere to 20 GM/year QL; topical glaucoma/inflammation regimens should consider limit.
    inv-109: bimatoprost ophthalmic
    Bimatoprost ophthalmic QLQL (0.1 ML per 1 day)
    Therapeutic classListed under Glaucoma agents with daily ML limit.
    Dispensing implicationDaily ML limit affects quantity dispensed for glaucoma therapy.
    inv-110: albuterol sulfate HFA
    Albuterol HFA QLQL (1.2 GM per 1 day)
    Nebulization solution QLalbuterol nebulization solution 2.5 mg/3 mL — QL (18 ML per 1 day)
    Inhaled product limitsDifferent inhaled formulations have distinct QLs; check product and ML/GM units.
    inv-111: albuterol nebulization solution 2.5 mg/3 ml
    Albuterol nebulization QLQL (18 ML per 1 day) for 2.5 mg/3 mL solution
    Multiple strengths notedOther nebulization strengths show different QLs (12.5 ML per day, 5 EA per day etc.).
    Provider noteEnsure correct ML/day QL is applied for the specific nebulized strength prescribed.
    inv-112: fluticasone-salmeterol inhalation powder
    Fluticasone‑salmeterol inhalation powder QLQL (2 EA per day)
    Formulary flagListed with M; QL in Respiratory tract section.
    Dispensing implicationTwo inhaler devices per day limit — confirm unit (EA) when processing claims.
    inv-113: ambrisentan
    Ambrisentan QLQL (1 EA per 1 day)
    Bosentan QLQL (2 EA per 1 day)
    PA requirementBoth ambrisentan and bosentan noted with PA; QL — prior authorization required before coverage.
    inv-114: bosentan
    Bosentan QLQL (2 EA per 1 day)
    PA flagBosentan listed with PA; QL in pulmonary hypertension agents section.
    Coverage implicationPA and per‑day EA limits must be met for coverage of bosentan.

    Specialty Pharmacy and Site-of-Care Requirements

    Prior Authorization

    Specialty‑pharmacy fill requirement for most specialty medications

    Most specialty medications must be filled at a network Specialty Pharmacy (Optum Specialty Pharmacy) to be covered; prescribers and staff must ensure specialty prescriptions are routed to the network specialty pharmacy.

    • Specialty medications are limited to a 34‑day supply and must be filled at the listed Specialty Pharmacy.
    • Specialty Pharmacy offers care coordination, patient support, and handles specialty billing.

    Policy Background and Governance

    The Prescription Drug List (PDL) is maintained and reviewed by a multidisciplinary committee of practicing physicians and pharmacists. That committee evaluates medications for safety, effectiveness, adverse events, clinical advantage, and cost, and it governs formulary decisions such as tier placement, utilization management (PA, QL, ST), and specialty pharmacy designation. Reviews and updates occur on a recurring schedule to ensure the PDL reflects current clinical and cost-effectiveness evidence.

    Terms and Abbreviations

    inv-58: Generic vs Brand definition
    Generic vs BrandBrand name drugs are protected by patent until expiration; generics contain the same active ingredient and are FDA‑approved equivalents.
    Cost implicationGeneric drugs are typically less expensive than brand name drugs.
    Regulatory noteAll generic medications are approved by the FDA before release to market.
    inv-59: Generic equivalent vs generic alternative
    Generic equivalent vs generic alternativeGeneric equivalent contains the same active ingredient and works the same way; a generic alternative may have a different active ingredient but works similarly.
    Clinical choiceA generic alternative may be used when therapeutically similar but not chemically identical.
    Formulary useBlue KC distinguishes equivalents and alternatives when managing coverage and substitutions.
    inv-60: Maintenance drug definition
    Maintenance drug definitionA maintenance drug is medication used to treat a chronic condition; FDA‑approved for long‑term use and classified using Medispan.
    ExamplesChronic condition medications such as antihypertensives or diabetes agents may be classified as maintenance drugs.
    Benefit implicationsMaintenance drugs may have different refill or coverage rules (e.g., 90‑day fills) per plan benefit design.
    inv-61: PA definition — Prior Authorization
    Prior Authorization (PA)PA requires prescriber to obtain approval from Blue KC before the drug will be covered; claims may be denied without prior approval.
    How to requestPrescribers must submit an electronic prior authorization request via the BlueKC provider portal (Providers > Forms > Prior Authorizations for Medications).
    RationalePA is used for safety, limited FDA‑approved uses, potential misuse, or availability of lower‑cost alternatives.
    inv-62: QL definition — Quantity Limit
    Quantity Limit (QL)Quantity Limit: the Plan limits the amount of the drug the plan will cover for certain drugs (expressed as units per time period).
    Expression formatExamples use numeric + unit + period (e.g., '1 EA per 1 day', '0.02 ML per 1 day').
    ImpactDispensing beyond QL may require prior authorization or be denied at claim adjudication.
    inv-63: ST definition — Step Therapy
    Step Therapy (ST)ST: the Plan may require trial of specified preferred drugs first before covering another drug for that condition.
    Failure criteriaIf first‑line drugs are inappropriate, prescriber must submit a PA documenting why alternatives are unsuitable.
    Formulary flagDrugs subject to ST are marked 'ST' in the formulary listings.
    inv-64: QL / PA / M / ST — formulary shorthand definitions
    Formulary shorthand (QL/PA/M/ST)QL = Quantity Limit; PA = Prior Authorization; M = Medical management/other restriction; ST = Step Therapy — used as shorthand on formulary entries.
    InterpretationPresence of these flags implies utilization management actions (e.g., documentation, PA submission, step trial).
    Denial riskClaims may be denied or limited when these flags are present and requirements unmet.
    inv-65: QL examples definition
    QL examples definitionQL examples in the document show numeric limits like '1 EA per 1 day', '0.02 ML per 1 day', '20 ML per 365 days' to convey allowed quantity over time.
    Units usedUnits include EA (each), ML (milliliter), GM (gram), and supply counts across periods (per day, per 30 days, per 365 days).
    Usage noteAlways check the specific formulation and timeframe on the formulary entry when applying a QL.
    inv-66: PA shorthand definition
    PA shorthand definitionPA = Prior Authorization — prescriber must obtain approval prior to fill for coverage.
    Where shownDisplayed alongside drug names in the formulary (e.g., 'PA; QL').
    ConsequenceNo PA may result in claim denial as listed in the policy.
    inv-67: ST shorthand definition
    ST shorthand definitionST = Step Therapy — indicates formulary requires trial of preferred agent(s) first.
    Documenting failureIf step agents are inappropriate, prescribers must submit PA documenting reason for exception.
    Formulary markingDrugs subject to ST are marked 'ST' in listings (examples across sections).
    inv-68: M / ACA flags definition
    M / ACA flags definitionM and ACA are restriction flags used to denote specific coverage restrictions or Affordable Care Act preventive categorizations (ACA-listed contraceptives may have special coverage).
    Practical effectACA‑flagged contraceptives may be covered as preventive care — check member benefits for cost sharing.
    DocumentationM indicates medical management restrictions that may require additional review or PA.
    inv-69: Index of Drugs — alphabetical listing
    Index of DrugsAlphabetical listing/index of drugs referenced elsewhere in the policy document; used for cross‑reference to formulary sections.
    PurposeProvides quick lookup of drug names and page/section references within the PDL.
    LimitationIndex entries do not themselves include coverage rules — see formulary section for QL/PA/ST details.